Eurofins Biopharma Product Testing (BPT) Italy and Cellply announce strategic partnership to foster cell and gene therapy development through single-cell characterisation

MILANO, Italy, August 29, 2024 –Eurofins Biopharma Product Testing (BPT) Italy and Cellply Srl today announce a strategic partnership, which will enable cellular therapy developers to access Cellply’s unique platform which supports the comprehensive characterisation of cells and cell functions at single-cell resolution.

VivaCyte ^® – a tool capable of reducing development times, costs, and risks – is the first fully integrated platform of its kind to characterize the complex functionality and mechanism of action of potential cellular immunotherapies rapidly and comprehensively.

Delivered via the VivaCyte platform, this in-depth characterisation offers an unprecedented ability to deliver greater product and process consistency and speed of development. VivaCyte allows for the evaluation of both potency and immunophenotype at single cell level. Such data can result in the rapid identification of the best gene edits, identification of the most suitable donors, and determine the most appropriate conditions for expansion.

As part of this strategic partnership, Eurofins BPT Italy, part of the global Eurofins network of laboratories — a world leader in pharmaceutical testing, and one of the market leaders in biopharma contract development and manufacturing, will perform analysis of customers’ products using the VivaCyte system. Eurofins BPT Italy will be the first laboratory to offer ready access to Cellply’s technology to the global cellular immunotherapy community, providing them with in-depth information including multiparametric potency analysis, killing data, cytokine release and immunophenotyping, all at single-cell resolution.

Emiliano Spagnolo, CEO of Cellply, added, “Users of VivaCyte understand the capability of the system to rapidly deliver the depth of experimental functional analysis data they require. We are pleased to have established this strategic partnership with the expert cell and gene therapy team at Eurofins Biopharma Product Testing Italy to make our technology more widely available to small and mid-sized drug development organisations.”

About Cellply

Cellply is a biology-focused deep tech company developing tools to unravel the complexity of the immune system and enable rapid development of new immunotherapies and cell-based therapies with enhanced potency and persistence.

Headquartered in Bologna, Italy, the team is creating state-of-the-art analytical solutions capable of robustly characterising these exciting therapeutic modalities at single-cell resolution.

Cellply has combined patented microfluidic technology and AI-powered automated image analysis capability with comprehensive automation and dedicated software to create its flagship product VivaCyte^®.

Today Cellply is focused on enhancing research and development of cell therapies, illustrated by the recent publication in the journal Nature Biotechnology entitled Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalised T cell therapy. featuring VivaCyte data.  Tomorrow its ambition is to dramatically reduce cost and complexity of quality control for these promising innovative therapies.

Media contact: press@cellply.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With ca. 62,000 staff across a network of more than 900 laboratories in over 1,000 companies in 62 countries,

Eurofins offers a portfolio of over 200,000 analytical methods. Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.

For further information please contact: InfoFarma@eurofins.com
To find out more visit: www.eurofins.it/BioPharma